54826-14-1

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-BROMO-4-CHLOROPHENYL)ETHANONE is used as a synthetic intermediate for the production of various pharmaceuticals, contributing to the development of new drugs and medications due to its unique chemical structure and reactivity.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(3-BROMO-4-CHLOROPHENYL)ETHANONE serves as a key intermediate in the synthesis of agrochemicals, aiding in the creation of pesticides and other agricultural chemicals to protect crops and enhance yields.
Used in Organic Synthesis:
1-(3-BROMO-4-CHLOROPHENYL)ETHANONE is utilized as a reactant in organic synthesis processes, where its bromine and chlorine atoms allow for a variety of chemical reactions, leading to the formation of diverse organic compounds.
Used in Research:
1-(3-BROMO-4-CHLOROPHENYL)ETHANONE is also employed in research settings for studying chemical reactions and exploring new synthetic pathways, furthering the understanding of organic chemistry and its applications.

Upstream product

• 79406-57-8 3-amino-4-chloroacetophenone 
• 694-80-4 2-bromo-1-chlorobenzene 
• 75-36-5 acetyl chloride 
• 99-91-2 para-chloroacetophenone 
• 203179-00-4 3-bromo-4-chloro-N-methoxy-N-methylbenzamide 
• 75-16-1 methylmagnesium bromide 
• 56759-32-1 1-(4-amino-3-bromophenyl)-ethanone 
• 544-92-3 copper(I) cyanide 

Downstream Products

• 1025772-35-3 1-(3-bromo-4-chlorophenyl)-N-((R)-1-(3-chlorophenyl)ethyl)ethanamine 

Relevant academic research and scientific papers

Synthesis method for aromatic ring bromination of acetophenones derivative

The invention relates to a synthesis method for aromatic ring bromination of an acetophenones derivative, and belongs to the technical field of organic synthesis. The synthesis method consists of twokinds of synthesis methods: method A, adding the acetophenone derivative into a first oxidizing agent and stirring to form a suspension system, controlling the temperature of the suspension system tobe 10-50 DEG C, adding a first reducing agent or a second reducing agent, stirring and reacting for 2-20 h, and performing aftertreatment after the reaction is completed to obtain the aromatic ring brominated acetophenone derivative; method B, adding the acetophenone derivative into the second reducing agent and stirring to form a suspension system, controlling the temperature of the suspension system to be 10-50 DEG C, then adding a second oxidizing agent or the first oxidizing agent, stirring and reacting for 2-20 h, and performing aftertreatment after the reaction is completed to obtain thearomatic ring brominated acetophenone derivative. According to the synthesis method provided by the invention, an inorganic and non-toxic bromination reagent is used, water is used as a reaction solvent, the prepared product is mutually incompatible with water, so that separation and the aftertreatment are convenient to perform, therefore, the synthesis method of the invention is applicable to large-scale industrial production of intermediate products for aromatic ring bromination of the acetophenones derivative.

PHOSPHONATE COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula (I), or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is a phosphonate substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Isoquinolinium Dichromate and Chlorochromate as Efficient Catalysts for Oxidative Halogenation of Aromatic Compounds under Acid-Free Conditions

Isoquinolinium dichromate and isoquinolinium chlorochromate were found as efficient catalysts to trigger oxidative bromination and iodination of aromatic hydrocarbons with KBr/KI and KHSO4 under acid-free conditions. Reaction times reduced highly significantly under sonication, followed by corresponding mono bromo derivatives in very good yield with high regioselectivity.

Novel small molecule inhibitors targeting the "switch region" of bacterial RNAP: Structure-based optimization of a virtual screening hit

Rising resistance against current antibiotics necessitates the development of antibacterial agents with alternative targets. The "switch region" of RNA polymerase (RNAP), addressed by the myxopyronins, could be such a novel target site. Based on a hit can

Diazinones as P2 replacements for pyrazole-based cathepsin S inhibitors

A pyridazin-4-one fragment 4 (hCatS IC50 = 170 μM) discovered through Tethering was modeled into cathepsin S and predicted to overlap in S2 with the tetrahydropyridinepyrazole core of a previously disclosed series of CatS inhibitors. This fragment served as a template to design pyridazin-3-one 12 (hCatS IC50 = 430 nM), which also incorporates P3 and P5 binding elements. A crystal structure of 12 bound to Cys25Ser CatS led to the synthesis of the potent diazinone isomers 22 (hCatS IC50 = 60 nM) and 27 (hCatS IC50 = 40 nM).

4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES

The present invention relates to a compounds of formula I wherein R1, R1′, R2, R3, R4, X, Ar, and m are as defined in the specification and claims and pharmaceutically active acid addition salts thereof. Compounds of the invention have Asp2 (β-secretase, BACE 1 or Memapsin-2) inhibitory activity and are useful for the treatment of diseases characterized by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.

Calcium receptor modulating agents

The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.